HEALIOS K.K. has been moving forward with efforts to create next generation immunotherapies for solid tumors by combining its iPS cell and gene editing technology expertise. In this notice the company disclosing that have decided to add the development of allogeneic, iPS cell derived gene-modified natural killer (NK) cells to its pipeline (development code: HLCN061). The advent of molecular targeted agents and immunotherapy has led to improved results of cancer treatment; however, the field is still in need of further treatment methods. This is especially true of solid tumors, which is a current area of tremendous unmet medical need. Solid tumors refer generally to cancers that appear in organs and systems other than the blood. There is no special expense to start this development and research. The company expects that steady promotion of this development and research will lead to future sales revenue and corporate value.